Is BPC-157 legal? Status by country

Is BPC-157 legal in the US?

BPC-157 is not FDA-approved, and it isn't part of any approved drug¹. That shuts it out of the normal routes into a pharmacy. Federal law lets a 503A compounding pharmacy use a bulk ingredient only if it has a USP monograph, is part of an FDA-approved drug, or is on FDA's 503A Bulks List². FDA says BPC-157 has no USP monograph and isn't part of an approved drug¹, and it isn't on the list.

FDA's briefing also notes that BPC-157 is sold in the US as a dietary supplement ingredient, in capsules and tablets, and that some websites sell it labeled “for research purposes only”¹. Neither of those is an FDA approval. FDA has said in warning letters to peptide sellers that a “research use only” label doesn't stop a product being treated as an unapproved drug when the seller's own website shows it's meant for people¹².

The research use only guide covers what that label means in more detail.

What did the FDA advisory committee decide on BPC-157 in July 2026?

On July 23, 2026, FDA's Pharmacy Compounding Advisory Committee discussed whether BPC-157 should go on the 503A Bulks List, looking at its use for ulcerative colitis³. FDA's question paper asked for two votes, one on BPC-157 free base and one on BPC-157 acetate⁴.

FDA's own reviewers recommended against both. They said BPC-157 isn't well characterized, raised concerns about immune reactions from impurities and clumping in injected forms, and found that the data don't support using it for ulcerative colitis. They also found too little safety information in people to describe its risks¹. ABC News reported that the committee voted 8 to 6, with 1 abstention, in favor of adding BPC-157⁵. When we checked on November 8, 2026, FDA had not posted minutes or an official vote count on the meeting page³.

• The vote is advice, not a decision. FDA's meeting page says advisory committees make non-binding recommendations³. FDA says it won't make a final determination until it has weighed the committee's input and finished its reviews².
• Adding it would take a regulation. The law says the 503A Bulks List is developed through regulations². Until FDA does that, BPC-157 isn't on the list.

Was BPC-157 on FDA's Category 2 list?

Yes, in the past. FDA placed BPC-157 in Category 2, its list of bulk substances that may raise significant safety risks. The nominations that brought it to FDA were later withdrawn, so FDA now lists it under “nominated but withdrawn” (page dated April 22, 2026)⁶. FDA's current Category 2 list, updated May 14, 2026, doesn't include it⁷.

Leaving Category 2 didn't mean FDA cleared it. FDA's note on that page still says BPC-157 may carry a risk of immune reactions, may have impurity problems, and that the agency has little or no safety information on it⁶. FDA then reviewed BPC-157 on its own initiative for the July 2026 meeting¹.

BPC-157 legal status by country

BPC-157 has no approval as a medicine in any of these countries. The table shows what the rules say beyond that.

Is BPC-157 legal in the UK?

There is no licensed BPC-157 medicine in the UK. The TGA found it wasn't listed in the MHRA's product database in 2023⁹, and FDA found no approved product in any country in 2026¹.

Under UK law, a product is a medicine if it's presented as treating or preventing disease, or if it's used to change how the body works through a pharmacological, immunological or metabolic action¹⁰. The MHRA decides this case by case, looking at claims, ingredients, websites, social media and customer reviews¹⁰. We couldn't find an MHRA statement that names BPC-157 specifically.

Is BPC-157 legal in Australia?

In Australia, BPC-157 is a Schedule 4 prescription-only medicine. It's also listed in Appendix D, clause 5 of the Poisons Standard, which covers poisons that “must not be possessed by a person without authority (for example, possession other than in accordance with a legal prescription)”⁸.

The TGA proposed this in 2023. Its reasons included that BPC-157 is an experimental therapy with no clinical data in humans, and that similar peptides such as thymosin beta-4, CJC-1295 and ipamorelin were already in Schedule 4⁹. At that time no medicine containing BPC-157 was on the Australian Register of Therapeutic Goods⁹.

Is BPC-157 legal in Canada?

No BPC-157 product is authorized for sale in Canada. Health Canada's Drug Product Database returns no product with BPC-157 as an ingredient¹³. Health Canada says injectable peptides are generally regulated as prescription drugs, and that unauthorized drug products are illegal¹¹.

In an April 2026 advisory, Health Canada listed BPC-157 among injectable peptides it had seized. It said products labeled “For Research Use Only – Not for Human Consumption” are not legal or exempt from the rules because of that label¹¹. In May 2026, a supplier recalled BPC-157 powder sold to compounding and community pharmacies, because it was an unauthorized active ingredient¹⁵.

Is BPC-157 banned in sport?

Yes. The WADA 2026 Prohibited List names BPC-157 in class S0, non-approved substances, which are prohibited at all times, in and out of competition¹⁴. S0 covers any drug with no current approval from a government health regulator for human use¹⁴. BPC-157 has been named on the WADA list since January 2022⁹.

For what the studies found, see the BPC-157 overview and BPC-157 vs TB-500.